Preventing first variceal hemorrhage in cirrhosis

Journal of Clinical Gastroenterology

Volumn 41, Issue SUPPL. 3, 2007, Pages

  Albillos, Agustín ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Cirrhosis; Portal hypertension; Primary prophylaxis

Indexed keywords

BETA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; NADOLOL; PLACEBO; SPIRONOLACTONE;

BETA ADRENERGIC RECEPTOR BLOCKING; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; DIET THERAPY; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGUS VARICES; ESOPHAGUS VARICES BLEEDING; HUMAN; LIVER CIRRHOSIS; META ANALYSIS; MONOTHERAPY; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PRIMARY PREVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STOMACH VARICES; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; VEIN LIGATION;

ADRENERGIC BETA-ANTAGONISTS; ENDOSCOPY; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYPERTENSION, PORTAL; LIGATION; LIVER CIRRHOSIS; PATIENT SELECTION; PORTAL PRESSURE; PRACTICE GUIDELINES AS TOPIC; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 35848933212     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318150d3c6     Document Type: Conference Paper

References (50)

1. D'Amico G. Esophageal varices: from appearance to rupture: natural history and prognostic indicators. In: Groszmann RJ, Bosch J, eds. Portal Hypertensión in the 21st Century. Dortrecht: Kluwer Academia Publishers; 2004: 147-154.
2. Chalasani N, Kahi C, Francois F, et al. Improved patient survival after acute variceal bleeding: a multicenter, cohort study. Am J Gastroenterol. 2003;98:653-659.
3. D'Amico G, De Franchis R, Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003;38:599-612.
4. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652-659.
5. Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38:266-272.
6. Pagliaro L, D'Amico G, Pasta L, et al. Portal hypertension in cirrhosis: natural history. In: Bosch J, Groszmann RJ, eds. Portal Hypertension: Pathophysiology and Treatment. Oxford: Blackwell-Science; 1992:72-92.
7. Madhotra R, Mulcahy HE, Willner I, et al. Prediction of esophageal varices in patients with cirrhosis. J Clin Gastroenterol. 2002;34:81-85.
8. The North Italian Endoscopic Club for the Study and Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983-989.
9. Merkel C, Zoli M, Siringo S, et al. Prognostic indicators of risk for first variceal bleeding in cirrhosis: a multicenter study in 711 patients to validate and improve the North Italian Endoscopic Club (NIEC) index. Am J Gastroenterol. 2000;95:2915-2920.
10. Nevens F, Bustami R, Scheys I, et al. Variceal pressure is a factor predicting the risk of a first variceal bleeding: a prospective cohort study in cirrhotic patients. Hepatology. 1998;27:15-19.
11. Lebrec D, De Fleury P, Rueff B, et al. Portal hypertension, size of esophageal varices, and risk of gastrointestinal bleeding in alcoholic cirrhosis. Gastroenterology. 1980;79:1139-1144.
12. Gluud C, Henriksen JH, Nielsen G. Prognostic indicators in alcoholic cirrhotic men. Hepatology. 1988;8:222-227.
13. Paquet KJ, Kalk JF, Klein CP, et al. Prophylactic sclerotherapy for esophageal varices in high-risk cirrhotic patients selected by endoscopic and hemodynamic criteria: a randomized, single-center controlled trial. Endoscopy. 1994;26:734-740.
14. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475-505.
15. Poynard T, Cales P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med. 1991;324:1532-1538.
16. Albillos A, Banares R, Gonzalez M, et al. Value of the hepatic venous pressure gradient to monitor drug therapy for portal hypertension: a meta-analysis. Am J Gastroenterol. 2007;102:1116-1126.
17. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611-1624.
18. Feu F, Bordas JM, Luca A, et al. Reduction of variceal pressure by propranolol: comparison of the effects on portal pressure and azygos blood flow in patients with cirrhosis. Hepatology. 1993;18:1082-1089.
19. Aracil C, Colomo I, Ordas C, et al. Acute hemodynamic response to beta-blockers for the prediction of long-term outcome in primary prophylaxis of variceal bleeding. Final results of a prospective study. J Hepatol. 2007;46(suppl 1):S35.
20. Garcia-Pagan JC, Feu F, Bosch J, et al. Propranolol compared with propranolol plus isosorbide-5-mononitrate for portal hypertension in cirrhosis. A randomized controlled study. Ann Intern Med. 1991;114:869-873.
21. Pietrosi G, D'amico G, Pasta L, et al. Isosorbide mononitrate (IMN) with nadolol compared to nadolol alone for prevention of first bleeding in cirrhosis. A double blind placebo-controlled randomized trial. J Hepatol. 1999;30(S1):66.
22. Merkel C, Bolognesi M, Sacerdoti D, et al. The hemodynamic response to medical treatment of portal hypertension as a predictor of clinical effectiveness in the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2000;32:930-934.
23. Garcia-Pagan JC, Morillas R, Bañares R, et al. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology. 2003;37:1260-1266.
24. Albillos A, Pérez M, Cacho G, et al. Accuracy of portal and forearm blood flow measurements in the assessment of portal pressure response to propranolol. J Hepatol. 1997;27:496-504.
25. Albillos A, Garcia-Pagan JC, Iborra J, et al. Propranolol plus prazosin compared with propranolol plus isosorbide-5- mononitrate in the treatment of portal hypertension. Gastroenterology. 1998;115:116-123.
26. Abecasis R, Kravetz D, Fassio E, et al. Nadolol plus spironolactone in the prophylaxis of first variceal bleed in nonascitic cirrhotic patients: a preliminary study. Hepatology. 2003;37:359-365.
27. Beppu K, Inokuchi K, Koyanagi N, et al. Prediction of variceal hemorrhage by esophageal endoscopy. Gastrointest Endosc. 1981;27:213-218.
28. Zoli M, Merkel C, Magalotti D, et al. Evaluation of a new endoscopic index to predict first bleeding from the upper gastrointestinal tract in patients with cirrhosis. Hepatology. 1996;24:1047-1052.
29. Andreani T, Poupon RE, Balkau BJ, et al. Preventive therapy of first gastrointestinal bleeding in patients with cirrhosis: results of a controlled trial comparing propranolol, endoscopic sclerotherapy and placebo. Hepatology. 1990;12:1413-1419.
30. Conn HO, Grace ND, Bosch J, et al. Propranolol in the prevention of the first hemorrhage from esophagogastric varices: A multicenter, randomized clinical trial. The Boston-New Haven-Barcelona Portal Hypertension Study Group. Hepatology. 1991;13:902-912.
31. Merkel C, Marin R, Angeli P, et al. A placebo-controlled clinical trial of nadolol in the prophylaxis of growth of small esophageal varices in cirrhosis. Gastroenterology. 2004;127:476-484.
32. Cales P, Oberti F, Payen JL, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis: a randomized trial. French-Speaking Club for the Study of Portal Hypertension. Eur J Gastroenterol Hepatol. 1999;11:741-745.
33. Laine L, Cook D. Endoscopic ligation compared with sclerotherapy for treatment of esophageal variceal bleeding. A meta-analysis. Ann Intern Med. 1995;123:280-287.
34. Imperiale TF, Chalasani N. A meta-analysis of endoscopic variceal ligation for primary prophylaxis of esophageal variceal bleeding. Hepatology. 2001;33:802-807.
35. Triantos C, Vlachogiannakos J, Armonis A, et al. Primary prophylaxis of variceal bleeding in cirrhotics unable to take beta-blockers: a randomized trial of ligation. Aliment Pharmacol Ther. 2005;21:1435-1443.
36. Chen C, Sheu M, SU S. Prophylactic endoscopic variceal ligation (EVL) with multiple band ligator for esophageal varices. Gastroenterology. 1998;144:A1224.
37. De BK, Ghoshal UC, Das T, et al. Endoscopic variceal ligation for primary prophylaxis of oesophageal variceal bleed: preliminary report of a randomised controlled trial. J Gastroenterol Hepatol. 1999;14:220-224.
38. Sarin SK, Lamba GS, Kumar M, et al. Comparison of endoscopic ligation and propranolol for the primary prevention of variceal bleeding. N Engl J Med. 1999;340:988-993.
39. Song I, Shin J, Kim I, et al. A prospective randomised trial between the prophylactic endoscopic variceal ligation and propranolol administration for prevention of first bleeding in cirrhotic patients with high-risk esophageal varices. J Hepatol. 2000;32(suppl 2):41.
40. De la Mora J, Farca-Belsaguy A, Uribe M, et al. Ligation vs propranolol for primary prophylaxis of variceal bleeding using a multiple band ligator and objective measurements of treatment adequacy: preliminary results. Gastroenterology. 2000;1118:6512.
41. Lui HF, Stanley AJ, Forrest EH, et al. Primary prophylaxis of variceal haemorrhage: a randomised controlled trial comparing band ligation, propranolol, and isosorbide mononitrate. Gastroenterology. 2002;123:735-744.
42. Gheorge C, Gheorge L, Vadan R, et al. Prophylactic banding ligation of high risk esophageal varices in patients on the waiting list for liver transplantation: an interim report. J Hepatol. 2002;36(suppl 1):38.
43. Lo GH, Chen WC, Chen MH, et al. Endoscopic ligation vs. nadolol in the prevention of first variceal bleeding in patients with cirrhosis. Gastrointest Endosc. 2004;59:333-338.
44. Schepke M, Kleber G, Nurnberg D, et al. Ligation versus propranolol for the primary prophylaxis of variceal bleeding in cirrhosis. Hepatology. 2004;40:65-72.
45. Drastich P, Lata J, Petryl J, et al. Endoscopic variceal band ligation in comparison with propranolol in prophylaxis of first variceal bleeding in patients with liver cirrhosis. J Hepatol. 2005;42(suppl 2):79.
46. Jutabha R, Jensen DM, Martin P, et al. Randomised study comparing banding and propranolol to prevent initial variceal haemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology. 2005;128:870-881.
47. Thuluvath PJ, Maheshwari A, Jagannath S, et al. A randomised controlled trial of beta-blockers versus endoscopic band ligation for primary prophylaxis: a large sample size is required to show a difference in bleeding rates. Dig Dis Sci. 2005;50:407-410.
48. Psilopoulos D, Galanis P, Goulas S, et al. Endoscopic variceal ligation for prevention of first variceal bleeding: a randomized controlled trial. Eur J Hepatol. 2005;17:1111-1117.
49. Lay CS, Tsai YT, Lee FY, et al. Endoscopic variceal ligation versus propranolol in prophylaxis of first variceal bleeding in patients with cirrhosis. J Gastroenterol Hepatol. 2006;21:413-419.
50. Imperiale TF, Klein RW, Chalasani N. Cost-effectiveness analysis of variceal ligation vs. beta-blockers for primary prevention of variceal bleeding. Hepatology. 2007;45:870-878.